/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
Rajeev Nannapaneni is a risk-taker. And, the inspiration stems from no mean source. “As they say in the Bhagavad Gita, you can’t obsess too much about the outcome. You have to do what you’re supposed to do and then things will fall the way they fall, right?”
Wise words from the vice chairman and CEO of Natco Pharma and an attribute that has served the company well. So far.
In 2023-24, Natco posted revenue from operations of Rs 3,998 crore, a 47% jump largely fuelled by its generic version of the cancer drug Revlimid. What makes it better is …
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
